Impact of maintenance therapy on hospitalization and expenditures for medicare beneficiaries with chronic obstructive pulmonary disease

American Journal Geriatric Pharmacotherapy

Volumn 8, Issue 5, 2010, Pages 441-453

  Stuart, Bruce C ^a   Simoni Wastila, Linda ^a   Zuckerman, Ilene H ^a   Davidoff, Amy ^a   Shaffer, Thomas ^a   Yang, Hui Wen Keri ^a   Qian, Jingjing ^a   Dalal, Anand A ^b   Mapel, Douglas W ^c   Bryant Comstock, Lynda ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b GLAXOSMITHKLINE   (United States)

^c LOVELACE CLINIC FOUNDATION   (United States)

Author keywords

chronic obstructive pulmonary disease; hospitalization; maintenance therapy; Medicare costs; rehospitalization

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; INFLUENZA VACCINE; METHYLXANTHINE DERIVATIVE; PNEUMOCOCCUS VACCINE;

ADULT; AGED; ARTICLE; ASIAN; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG COST; DRUG USE; EUROPEAN AMERICAN; FEMALE; HEALTH CARE COST; HISPANIC; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; INFLUENZA VACCINATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICARE; PRESCRIPTION; PRIORITY JOURNAL; SMOKING;

AGED; AGED, 80 AND OVER; AGING; COMORBIDITY; DRUG PRESCRIPTIONS; FEMALE; HEALTH CARE COSTS; HEALTH CARE SURVEYS; HOSPITALIZATION; HUMANS; MALE; MEDICARE; MEDICATION ADHERENCE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PRACTICE GUIDELINES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; UNITED STATES;

EID: 79951863731     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2010.10.002     Document Type: Article

References (47)

1. CJ Murray, and AD Lopez Evidence-based health policylessons from the Global Burden of Disease Study Science 274 1996 740 743 (Pubitemid 26398244)
2. DM Mannino, DM Homa, and LJ Akinbami Chronic obstructive pulmonary disease surveillance-United States, 1971-2000 MMWR Surveill Summ 51 2002 1 16
3. EF Wouters Economic analysis of the Confronting COPD survey: An overview of results Respir Med 97 Suppl C 2003 S3 S14
4. American Lung Association. Epidemiology & Statistics Unit, Research and Program Services. Trends in chronic obstructive bronchitis and emphysema: Morbidity and mortality.
5. http://breathehealthy.org/images/uploads/2007-COPD-Trend-Report.pdf August 25, 2009 Accessed
6. MT Halpern, RH Stanford, and R Borker The burden of COPD in the USA: Results from the Confronting COPD survey Respir Med 97 Suppl C 2003 S81 S89
7. AL Stewart, S Greenfield, and RD Hays Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study [published correction appears in JAMA. 1989;262:2542] JAMA 262 1989 907 913 (Pubitemid 19208947)
8. D Tinkelman, RJ Nordyke, and S Isonaka The impact of chronic obstructive pulmonary disease on long-term disability costs J Manag Care Pharm 11 2005 25 32
9. F Holguin, E Folch, SC Redd, and DM Mannino Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001 Chest 128 2005 2005 2011 (Pubitemid 41507534)
10. AF Connors Jr, NV Dawson, C Thomas for the SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments) Outcomes following acute exacerbation of severe chronic obstructive lung disease [published correction appears in Am J Respir Crit Care Med. 1997;155:386] Am J Respir Crit Care Med 154 1996 959 967
11. CM Roberts, D Lowe, and CE Bucknall Clinical audit indicators of outcome following admission to hospital with acute exacerbation of chronic obstructive pulmonary disease Thorax 57 2002 137 141 (Pubitemid 34123887)
12. KH Groenewegen, AM Schoos, and EF Wouters Mortality and mortality-related factors after hospitalization for acute exacerbation of chronic obstructive pulmonary disease Chest 124 2003 459 467 (Pubitemid 37000120)
13. AM Yohannes, RC Baldwin, and MJ Connolly Predictors of 1-year mortality in patients discharged from hospital following acute exacerbation of chronic obstructive pulmonary disease Age Ageing 34 2005 491 496 (Pubitemid 41282855)
14. National Institutes of Health, National Heart, Lung, and Blood Institute. Morbidity & Mortality: 2007 Chart Book on Cardiovascular, Lung, and Blood Diseases. 2007.
15. http://www.nhlbi.nih.gov/resources/docs/2009-ChartBook.pdf August 25, 2009 Accessed
16. B Stuart, L Simoni-Wastila, and I Zuckerman Medication use by aged and disabled Medicare beneficiaries across the spectrum of morbidity: A chartbook 2007 The Peter Lamy Center on Drug Therapy and Aging, University of Maryland School of Pharmacy Baltimore, Md
17. J Menzin, L Boulanger, and J Marton The economic burden of chronic obstructive pulmonary disease (COPD) in a US Medicare population Respir Med 102 2008 1248 1256
18. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease.
19. http://www.goldcopd.com/Guidelineitem.asp?ll=2&12=1&intId=2003 March 19, 2009 Accessed
20. American Thoracic Society. American Thoracic Society and European Respiratory Society standards for the diagnosis and management of patients with COPD.
21. http://www.thoracic.org/clinical/copd-guidelines/resources/copddoc.pdf August 25, 2009 Accessed
22. M Cazzola, and NA Hanania The role of combination therapy with corticosteroids and long-acting beta2-agonists in the prevention of exacerbations in COPD Int J Chron Obstruct Pulmon Dis 1 2006 345 354
23. NA Hanania The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD Pulm Pharmacol Ther 21 2008 540 550 (Pubitemid 351625936)
24. M Mensing, and R Aalbers Comparison and optimal use of fixed combinations in the management of COPD Int J Chron Obstruct Pulmon Dis 2 2007 107 116 (Pubitemid 47202211)
25. PM Calverley, JA Anderson, B Celli for the TORCH investigators Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease N Engl J Med 356 2007 775 789 (Pubitemid 46294610)
26. M Friedman, and DE Hilleman Economic burden of chronic obstructive pulmonary disease. Impact of new treatment options PharmacoEconomics 19 2001 245 254 (Pubitemid 32230939)
27. MS Niederman, JS McCombs, and AN Unger Treatment cost of acute exacerbations of chronic bronchitis Clin Ther 21 1999 576 591 (Pubitemid 29198043)
28. MM Spence, R Hui, and J Chan Cost reduction strategies used by elderly patients with chronic obstructive pulmonary disease to cope with a generic-only pharmacy benefit J Manag Care Pharm 12 2006 377 382 (Pubitemid 47400594)
29. KL Rascati, M Akazawa, and M Johnsrud Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen Clin Ther 29 2007 1203 1213 (Pubitemid 47198879)
30. JM York, J Smeeding, and RA Brook Exploratory economic evaluation of patients with COPD on a combination product versus individual components (ipratropium bromide and albuterol) Adv Ther 24 2007 757 771 (Pubitemid 351612249)
31. AA Dalal, H Petersen, L Simoni-Wastila, and CM Blanchette Healthcare costs associated with initial maintenance therapy with fluticasone propionate 250 mug/salmeterol 50 mug combination versus anticholinergic bronchodilators in elderly US Medicare-eligible beneficiaries with COPD J Med Econ 12 2009 339 347
32. CS Rand Patient adherence with COPD therapy Eur Respir Rev 14 2005 97 101 (Pubitemid 43028766)
33. Health and Human Services (HHS), Centers for Medicare and Medicaid Services (CMS). Medicare current beneficiary survey (MCBS).
34. http://www.cms.gov/LimitedDataSets/11-MCBS.asp#TopOfPage August 25, 2009 Accessed
35. DW Mapel, MA Picchi, and JS Hurley Utilization in COPD: Patient characteristics and diagnostic evaluation Chest 117 2000 346S 353S (Pubitemid 30314465)
36. DW Mapel, GP McMillan, and FJ Frost Predicting the costs of managing patients with chronic obstructive pulmonary disease Respir Med 99 2005 1325 1333 (Pubitemid 41245321)
37. JA Poisal Reporting of drug expenditures in the MCBS Health Care Financ Rev 25 2003 23 36 (Pubitemid 38500729)
38. LA Rodrguez, MA Wallander, E Martn-Merino, and S Johansson Heart failure, myocardial infarction, lung cancer and death in COPD patients: A UK primary care study Respir Med 104 2010 1691 1699
39. GC Donaldson, JR Hurst, and CJ Smith Increased risk of myocardial infarction and stroke following exacerbation of COPD Chest 137 2010 1091 1097
40. United States Department of Labor, Bureau of Labor Statistics. Consumer Price Index.
41. http://www.bls.gov/cpi/tables.htm January 20, 2009 Accessed
42. A Briggs, M Spencer, and H Wang Development and validation of a prognostic index for health outcomes in chronic obstructive pulmonary disease Arch Intern Med 168 2008 71 79
43. BR Celli, CG Cote, and JM Marin The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease N Engl J Med 350 2004 1005 1012 (Pubitemid 38269277)
44. PW Jones, K Wilson, and S Sondhi Cost-effectiveness of salmeterol in patients with chronic obstructive pulmonary disease: An economic evaluation Respir Med 97 2003 2026
45. L Nannini, CJ Cates, TJ Lasserson, and P Poole Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease Cochrane Database Syst Rev 4 2007 CD003794
46. RD Restrepo, MT Alvarez, and LD Wittnebel Medication adherence issues in patients treated for COPD Int J Chron Obstruct Pulmon Dis 3 2008 371 384
47. L Blais, J Bourbeau, O Sheehy, and J LeLorier Inhaled corticosteroids in COPD: Determinants of use and trends in patient persistence with treatment Can Respir J 11 2004 27 32 (Pubitemid 38401254)